Published in Gene Therapy Weekly, September 19th, 2002
As part of this step forward, Quark will construct bioassays on target proteins selected by both Fujisawa and Quark and will perform high-throughput screening of the chemical libraries based on the bioassays developed. Quark will also continue the gene discovery and target validation program set forth under the original agreement.
Fujisawa has increased the annual research funding to Quark to cover the additional research program. Using Quark's technologies and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly